Collegium Pharmaceutical, Inc. (COLL) SEC Filings & Earnings Calls

Litigation resolved via settlement; $17M cash outflow; termination of license agreement removes future royalty obligations but may impact product economics.

“Payment of $17M; termination of Grünenthal License; no further royalties due.”

Share repurchase reduces cash reserves; final number of shares depends on stock price during the term.

“Final number of shares repurchased will be based on volume-weighted average prices during the term.” · word for word

Generic competition for Nucynta

“In January 2026, a generic version of Nucynta IR 50mg, 75mg, and 100mg tablets was approved...Hikma launched a generic version of Nucynta IR on February 25, 2026 and a generic version of Nucynta ER on March 11, 2026.” · word for word

High leverage and debt service

“We have substantial outstanding indebtedness...$865.5 million in principal was outstanding as of June 30, 2026...$241.5 million in 2.875% convertible senior notes due in 2029”

Dependence on key products

“Our ability to maintain profitability is dependent upon our ability to continue successfully commercializing our products and any products we may acquire in the future.” · word for word

Nucynta franchise revenue declining 24% YoY due to lower net pricing on authorized generics; guidance cut reflects this pressure.

“Nucynta Franchise net revenue $35.2M, down 24% YoY; guidance decrease in Product Revenues and Adj EBITDA largely driven by lower-than-expected AG Nucynta revenue due to lower net pricing.”

GAAP net loss of ($15.1M) vs prior year profit of $12.0M due to acquisition-related expenses; integration risk for AZSTARYS.

“GAAP net loss ($15.1M) vs income $12.0M; GAAP operating expenses +45% YoY; acquisition-related expenses included.”

Pain portfolio overall declining 9% YoY; Xtampza ER down 14%.

“Pain portfolio net revenues $140.9M, down 9% YoY; Xtampza ER $45.0M, down 14% YoY.”

Executive departures may cause disruption; integration risk from acquisition.

“CCO and CMO departing; acquisition integration ongoing.”

Generic competition for Nucynta Products

“Hikma launched a generic version of Nucynta IR on February 25, 2026 and a generic version of Nucynta ER on March 11, 2026.” · word for word

High leverage and debt service burden

“As of March 31, 2026, the outstanding principal balance of the 2025 Term Loan was $572.8 million... In addition, we have $241.5 million in 2.875% convertible senior notes due in 2029.” · word for word

Integration risk from Azstarys acquisition

“Our ability to realize the benefits of the acquisition of AZSTARYS is substantially dependent on the timely and effective integration of AZSTARYS.” · word for word

Opioid regulatory and litigation risk

“Social issues around the abuse of opioids, including law enforcement concerns over diversion of opioids and regulatory and enforcement efforts to combat abuse, could decrease the potential market for our opioid products and may adversely impact external investor perceptions of our business.” · word for word

Acquisition integration risk for AZSTARYS.

“Acquisition of AZSTARYS subject to closing conditions and integration.”

Minimal risk; routine board refreshment with no disagreement.

“Dr. Fallon’s decision ... not the result of any disagreement with the Company”

Concentration on Jornay PM for growth

“Jornay PM® generated $148.9 million in net revenue, representing 48% growth year-over-year compared to pro forma 2024 revenue” · word for word

Debt leverage from new credit facility

“In December 2025, we successfully closed an $980 million syndicated credit facility” · word for word

Regulatory approval risk for acquisition closing.

“Closing subject to HSR Act waiting period expiration or termination.”

Termination fee exposure of $24M if deal fails under certain conditions.

“Termination fee of $24 million payable by Company under specified circumstances.”

Generic competition risk for pain portfolio products.

“Hikma will have the exclusive right to sell the Collegium-supplied authorized generics of Nucynta and Nucynta ER.” · word for word

High leverage and debt service burden

“In December 2025, we entered into a Credit Agreement ... of which $580.0 million in principal was outstanding as of December 31, 2025 (the “2025 Term Loan”). In addition, we have $241.5 million in 2.875% convertible senior notes due in 2029 (the “2029 Convertible Notes”).” · word for word

FDA labeling changes for opioids

“On July 31, 2025, the FDA announced that it will be requiring safety related labeling changes for all opioid pain medications, including clearer risk information, dosing warnings, use limits, treatment guidance, safe discontinuation instructions, information on overdose reversal agents, an enhanced drug interaction warning, additional overdose risk informati” · word for word

Increased FDA scrutiny of advertising

“In September 2025, the FDA announced increased scrutiny of advertising and promotional practices, with a particular focus on direct-to-consumer (“DTC”) advertising, and released a large number of untitled and warning letters citing allegedly misleading claims in the marketing of prescription pharmaceutical products.” · word for word

Patent litigation risk

“We have been, and may continue to be, forced to litigate to enforce or defend our intellectual property rights against infringement and unauthorized use by competitors, and to protect our trade secrets, including in connection with our pending litigation against generic competitors that have filed Paragraph IV Certifications relating to certain of our produc” · word for word

Dependence on controlled substance regulations

“Some of our products contain controlled substances that are subject to state and federal laws and regulations regarding their manufacture, use, sale, importation, exportation and distribution.” · word for word

Increased debt load with $980M credit facility, though improved terms reduce interest burden.

“Credit facility includes $580M term loan, $300M delayed draw, and $100M revolver; quarterly amortization begins March 31, 2026.”

High Leverage and Debt Service

“We have substantial outstanding indebtedness, which may adversely affect our business, financial condition and results of operations... $581.3 million in principal was outstanding as of September 30, 2025... $241.5 million in 2.875% convertible senior notes due in 2029.” · word for word

Opioid Regulatory and Litigation Risk

“Our opioid products are subject to mandatory REMS programs... Unfavorable outcomes in intellectual property litigation could be costly and potentially limit our ability to commercialize our products.” · word for word

Concentration on Jornay PM and Ironshore Integration

“Our ability to maintain profitability is dependent upon our ability to continue successfully commercializing our products and any products we may acquire in the future.” · word for word

Concentration risk in Jornay PM and pain portfolio; regulatory or reimbursement changes could impact.

“Jornay PM and pain portfolio represent majority of revenue; any adverse regulatory action could affect growth.”

Increased adjusted operating expenses (up 60% YoY) may pressure margins if revenue growth slows.

“Adjusted operating expenses were $55.7M vs $34.8M in prior year, up 60%.”